Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #15010 on SiNtx Technologies Inc (SINT)
boston745
04/15/18 11:28 AM
#15012 RE: XenaLives #15010
With the initial research phase completed, Celling Biosciences will then translate the early findings to clinical trials in spinal and orthopedic applications. This collaborative research will further define the clinical advantages of silicon nitride in combination with stem cell-based therapies. Based on further scientific findings, the intellectual property from both partners could be leveraged to create innovative solutions that promote a robust nanotechnology.
04/16/18 1:27 PM
#15029 RE: XenaLives #15010